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Temozolomide, a chemotherapeutic drug that is often administered for the treatment of brain cancer 
has severe side effects and a poor aqueous solubility. In order to decrease the detrimental effect of 
the drug over healthy cells, a novel drug delivery vehicle was developed where the therapeutic drug 
was encapsulated within the hydrophobic cavities of b-CD modified magnetite nanoparticles, which 
are embedded in chitosan nanobeads prepared by salt addition. In-vitro studies have shown that the 
magnetic properties of the novel delivery vehicle are adequate for targeted drug delivery applications 
under an external magnetic field. Additionally, an increase in the amount of chitosan was shown 
to exhibit a strong shielding effect over the magnetic properties of the delivery vehicle, which lead 
to deterioration of the amount of captured drug at the targeted area, suggesting a delicate balance 
between the amounts of constituents composing the drug delivery vehicle. 
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INTRODUCTION
Chemotherapy is still the most widely used therapeutic 
approach in the management of cancer, in combination 
with surgery and radiation therapy. Temozolomide 
(TMZ), is a second generation imidazotetrazinone 
derivative with methylating properties, used as an 
oral cytotoxic agent for the adjuvant chemotherapy of 
malignant primary brain tumors, namely glioblastoma 
(Stupp et al., 2005) and malignant glioma (glioblastoma 
multiforme and anaplastic astrocytoma) (Brada et al., 
1999; Marchesi et al., 2007). The drug contains an 
imidazole group, which connects to a tetrazine ring. TMZ 
is presumed to have antitumor ability in the metabolism 
via chemical decomposition of the substance to 3-methyl-
(triazen-1-yl) imidazole-4-car-boxamide (MTIC), which 
is assumed to alkylate nucleophiles (Kim et al., 2001). 
This process is highly pH dependent since TMZ exerts 
its in-vivo activity by spontaneous hydrolyzation at 
physiologic pH (Andrasi et al., 2010). Further studies 
in rats and rhesus monkeys have shown that the level 
of TMZ in the cerebrospinal and brain are 30-40% of 
plasma concentration (Agarwala, Kirkwood, 2000). 
Temozolomide brings extensive additional benefits of 
crossing the blood brain barrier to its analogues DTIC (5-
(3, 3-dimethyl-1-triazenyl) imidazole-4-carboxamide), 
another member of the class of alkylating agent, which 
has a similar mechanism of action to metastatic melanoma 
that frequently metastasizes to the brain (Zuckerman et 
al., 2011). Additionally, Baker et al. (1999), conducted a 
study with 14C-TMZ in cancer patients and observed that 
a low interpatient variability in TMZ clearance suggests 
that TMZ administration will result in efficient generation 
of the active metabolite MTIC in all tissues where TMZ 
is present, which supports further therapeutic advantage 
of TMZ (Baker et al., 1999).
Aqueous solubility is considered as one of the major 
concerns of conventional chemotherapy as a result of 
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the mostly nonpolar characteristics of chemotherapeutic 
agents (Chidambaram, Manavalan, Kathiresan, 2011). 
Therefore, suitable delivery vehicles should be used to 
increase the solubility and the selectivity of conventional 
chemotherapeutic agents. Along with solubility, 
chemical stability of TMZ is also important. Once TMZ 
is delivered in the body, it quickly decomposes to its 
active agent, MTIC due to the neutral pH. Therefore, 
any delivery vehicle of the drug should be prepared in 
acidic solution and then lyophilized for stability. In some 
drug delivery systems, cyclodextrins (CDs) have been 
used to form inclusion complexes in order to increase 
the solubility of poorly soluble drugs, and enhance 
their bioavailability and stability (Tiwari, Tiwari, Rai, 
2010). CDs are cyclic oligosaccharides which contain 
at least six D-(+) glucopyranose units attached by α-(1, 
4) glycosidic bond (Eastburn, Tao, 1994). Due to their 
strong intermolecular hydrogen bonding, they have 
restricted solubility in aqueous medium. Replacement 
of the H-bond of the structure forming –OH group helps 
to enhance their solubility (Hakkarainen et al., 2005). 
Therefore, various derivatives of CDs are investigated 
such as hydroxyl-propyl derivatives and methylated 
b-CDs, etc (Del Valle, 2004). TMZ is shown to form 
inclusion complexes with different types of CDs and 
an increase in solubility during complex formation has 
been reported (Huang et al., 2008; Jain, Gursalkar, 
Bajaj, 2013; Swaminathan, Cavalli, Trotta, 2016).
Many serious side effects of chemotherapeutic 
drugs are widely presented in the literature (Hamzelou, 
2017; Coolbrandt et al., 2011; Bagot, 2015; Song et al., 
2014). Drug delivery systems have been developed in 
order to reduce these side effects and minimize the 
amount of drug administered to the human body. As 
these systems minimize the non-specific distribution 
of the drugs within the body causing invasion of 
healthy cells together with tumor cells, they enhance 
the efficiency of therapy and decrease the dose of the 
drug. The drug delivery systems are mainly composed 
of nanocarriers with core/shell structures. Amongst the 
many reported nanocarriers, magnetic nanoparticles 
predominantly iron oxides, are widely used due to 
their biocompatibility (Janko et al., 2017; Shaterabadi, 
Nabiyouni, Solymani, 2017; Patil et al., 2014). 
Moreover, it is possible to manipulate organization of 
the magnetic nanoparticles in solution by applying an 
external magnetic field, which allows for the needed 
accumulation of the particles as well as chemotherapeutic 




), which is also 
known as black iron oxide, is a naturally occurring 
mineral and exhibits the strongest magnetism of any 
transition metal oxide (Scwertmann, Cornell, 2006; 
Andrade-Eiroa et al., 2016). Additionally, magnetite is 
non-toxic, highly biocompatible and biodegradable, all 
of which make it a favorable candidate as a nanocarrier 
for targeted drug delivery systems (Kumar, Inbaraj, 
Chen, 2010). However, the overall performance of the 
drug delivery system containing magnetic nanoparticles 
as a transporter relies on the size, morphology and the 
magnetic properties of magnetite nanoparticles, as 
these properties affect the overall external targeting 
performance. Moreover, applied field strength as well 
as depth of the target tissue, rate of blood flow, and 
vascular supply play a role in the effectiveness of the 
corresponding drug delivery system. Most importantly, 
magnetite nanoparticles can also be used in parallel 
therapeutic approaches for cancer where particles can 
be targeted to the tumor site for hyperthermia, while 
active compound can be loaded onto the surface of 
the particles for drug delivery and specific antibodies 
can be conjugated for targeting purposes (Sun, Lee, 
Zhang, 2008).
In the core-shell structure of a drug delivery 
vehicle, apart from the core, a suitable shell also plays 
an important role. Chitosan is an amphiphilic, natural, 
non-toxic and biocompatible polymer which is reported 
to enhance the solubility of poorly soluble hydrophobic 
chemotherapeutic drugs such as paclitaxel, camptothecin 
and doxorubicine in drug delivery systems (Nam et al., 
2013; Bano et al., 2016; Qi et al., 2010). In addition to this 
effect over the solubility of the chemotherapeutic drugs, 
the polymeric chitosan micelles help passive targeting 
at the tumor site due to improved retention (EPR) effect 
and permeability (Riva et al., 2011), all of which make 
chitosan a suitable polymeric shell around the magnetic 
core for targeted drug delivery systems.
In this study, a new drug delivery system is 
developed for a chemotherapeutic agent, TMZ, using 
magnetic nanoparticles, CDs and chitosan to obtain 
a core-shell structure that can be manipulated by 
applying an external magnetic field. For this purpose, 
magnetite nanoparticles, which are coated with CDs, 
are synthesized by chemical co-precipitation method. 
Magnetite-chitosan nanobeads are synthesized by the 
ionic gelation method using these CD-coated magnetite 
nanoparticles. Finally, TMZ is incorporated in the 
chitosan-magnetite nanobeads to obtain the magnetic 
drug delivery system. 
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MATERIAL AND METHODS
Material
FeCl3 (anhydrous, 97%), FeSO4.7H2O (90%) 
and NaOH (99%) used in the synthesis of magnetite 
were obtained from Riedel-de Haen. TMZ (99.38%) 
was obtained from Koçak Farma (İstanbul, Turkey) 
as a gift and was used as received. Hydrochloric acid 
(37%, Sigma Aldrich), acetic acid (≥99.8%, Sigma 
Aldrich), methanol (99.7%, Sigma Aldrich) were used 
as received. b-Cyclodextrin (b-CD), Hydroxypropyl-b-
Cyclodextrin (H-b-CD), Hydroxypropyl-γ-Cyclodextrin 
(H-γ-CD) were purchased from Sigma Aldrich. In 
addition, medium molecular weight chitosan (Sigma 
Aldrich), Sodium Sulfate Decahydrate (99%, Sigma 
Aldrich) (Na2SO4.10H2O) were used. The water used 
was distilled by reverse osmosis using GFL 2004.
The cell line used in this study, Human umbilical 
vein endothelial cells (HUVEC), was obtained from 
the American type Culture Collection Corporation 
(ATCC-CRL-1730, Virginia, USA). The Dulbecco 
Eagle’s Minimum Essential Medium (DMEM; contains 
L-Glutamine, Gibco) was used. Infection of the cells 
was prevented using antimycotic (Anti-Anti (100X), 
Gibco) that was added to the medium as an antibiotic. 
Fetal bovine serum (FBS) was supplied from Gibco. 
Dulbecco’s Phosphate Buffered Salt Solution (DPBS; 
w/o: Calcium, w/o: Magnesium) was from PAN Biotech, 
GmbH. Dimethyl sulfoxide (DMSO) was supplied from 
Sigma-Aldrich, UK. Additionally, tetrazolium salt (MTS) 
was purchased from Promega Corporation (CellTiter 
96®Aqueous MTS Reagent Powder). HUVEC’s were 
grown in DMEM (1X) with high glucose content (4.5 
g/L) medium that contains %10 FBS, %1 penicillin-
streptomycin and %1 antimycotic. The cells were used 
in the logarithmic phase of growth and maintained at 
37 ºC in humidified 5% CO2 and 95% air.
METHODS
Synthesis of magnetite nanoparticles 
with b-CD, H-b-CD and H-γ-CD 
The synthesis of bare magnetite nanoparticles 
was carried out by the chemical co-precipitation 
method with some modifications (Petcharoen, Sirivat, 
2012). In a typical synthesis, 0.242 g FeSO4.7H2O 
and 0.282 g FeCl3 were dissolved in 80 mL de-aerated 
water along with 0.5 g b-CD. After complete mixing 
under mechanical stirring, while heating to 80 ºC 
and streaming N2(g) through the solution, 20 mL 
of 2.57 wt. % NaOH solution was quickly added to 
obtain a black suspension and the suspension was kept 
at 80 ºC for another 30 minutes under N2(g). After 
cooling to room temperature, magnetic nanoparticles 
were collected with magnetic separation and the 
nanoparticles obtained were washed with water. The 
concentration of the obtained magnetite solution was 
determined by Tiron chelation test (Yoe, Jones, 1944). 
The obtained nanoparticles were characterized as 
described elsewhere (Kleine et al., 2014). The same 
synthesis procedure was applied for the synthesis of 
magnetic nanoparticles which were functionalized 
with H-b-CD and H-γ-CD.
Characterization of magnetic nanobeads
The amounts of CDs on the surface of magnetite 
nanoparticles after synthesis are determined by using 
thermogravimetric analysis (TGA). TGA of the 
magnetite particles with and without cyclodextrins 
and only TMZ, only b-CD, TMZ-b-CD complex and 
TMZ-b-CD physical mixture are performed using a 
Perkin Elmer thermogravimetric analyzer at a heating 
speed of 10/min under nitrogen, where the temperature 
changes from 25 to 600 ºC . All samples are dried in 
a vacuum oven or by a freeze-dryer (SCANVAC, 
coolsafe) overnight. The size and morphology of the 
obtained magnetic nanobeads were investigated using 
a Scanning Electron Microscope (SEM) after being 
freeze-dried. Before measurement, the beads are coated 
with a thin layer of gold. The SEM used was a JEOL 
Ltd., JSM-5910LV at Boğaziçi University Advanced 
Technologies Research Center. The size distribution 
of these nanobeads was determined by Dynamic Light 
Scattering (DLS) taking an average of 10 consecutive 
measurements. The magnetic properties of the dried 
magnetic nanobeads are determined by Vibrating 
Sample Magnetometer (VSM). The instrument used 
was LDJ electronics 9600 and the measurements were 
taken between -15000 and +15000 Oe.
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Formation of magnetite-chitosan 
nanobeads with TMZ
The size and size distribution of the obtained 
particles are optimized by varying the nature of the salts 
(TPP and Na2SO4 were employed), its concentration, 
how the magnetite nanoparticles are introduced and 
the concentration of chitosan. While some of these 
procedures lead to the formation of undesired products, 
an optimized procedure can be described as follows. 
Chitosan in 1% acetic acid solution was prepared and 
a pre-determined amount of solid TMZ (0.01 g) was 
added, vortexed and sonicated for one minute followed 
by magnetic stirring for 30 minutes (chitosan-TMZ 
solution). 2.1 mg/mL aqueous magnetite solution was 
added to the aqueous Na2SO4.10H2O solution to obtain 
the final desired salt concentration (1.1 or 2.2 wt.% salt). 
While being magnetically stirred, the chitosan-TMZ 
solution was added dropwise by a Hamilton syringe to 
the magnetite-salt solution over one minute and the final 
solution is stirred for another 30 minutes. The obtained 
solution was then centrifuged at 6000 rpm for 15 minutes 
and the precipitated chitosan-magnetite nanobeads were 
collected. The amount of TMZ in the nanobeads was 
calculated by measuring the remaining TMZ amount in 
the supernatant using HPLC.
Targeting of TMZ with magnetic nanobeads
In order to explore the possibility of targeting 
magnetite-chitosan beads containing the chemotherapeutic 
agent TMZ, an in vitro experimental setup consisting of 
a peristaltic pump providing a constant flow of 55 mL/
min within 1.5 – 2 mm diameter tubing of 1 m length was 
prepared as shown in Figure 1. Additionally, handheld 
magnets generating a 0.3 – 0.5 T magnetic field were 
fixed at the test section, in order to collect magnetite-
chitosan beads containing chemotherapeutic agent TMZ 
during the flow.
The magnetic nanofluid was circulated continuously 
through the system for one hour in the presence of an 
external magnetic field applied at the test section. The 
magnets were then removed and the captured magnetite 
nanoparticles were collected by passing 1 M HCl 
solution from the system. The amount of magnetite 
nanoparticles captured in the test section was calculated 
by carrying out Tiron chelation test (Yoe, Jones, 1944) 
and the amount of TMZ captured at the targeted area 
was determined using HPLC.
FIGURE 1 - Schematic diagram of the targeting study. TMZ incorporated magnetic nanobeads are circulated via peristaltic 
pump and collected at the target site by using an external magnetic field.
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Quantification of TMZ by HPLC method
The HPLC method to quantify TMZ, which 
is given in detail elsewhere, was used with some 
modifications (Kim et al., 2001). Briefly, the HPLC 
system consists of 1525 Binary Pump, 2487 UV-Vis 
Detector, 717 Autosampler and a thermal column 
manager unit. X-Bridge 150 x 4.6, .5μm column was 
used and software was used to process the raw data. In 
HPLC, reverse phase C18 column (X-Bridge 150mmx 
.6cm, .5μm, Waters) was used. Water that contained 0.5 
vol.% acetic acid/methanol (80:20 v/v) was prepared 
for the mobile phase. A standard calibration curve 
was obtained with five different TMZ concentrations 
(R2=0.998) and three injections of three different 
samples were measured. Prior to measurement, the 
magnetite in the system was removed upon addition 





to Fe+3 (aq), which takes place overnight, as the 
presence of nanoparticles interferes with the HPLC 
measurements and clogs the column. 1 M HCl also 
helps to maintain the chemical stability of TMZ until 
the HPLC measurements.
Cell viability assay
To evaluate in vitro cytotoxicity of chitosan 
coated magnetite nanoparticles, the tetrazolium 
salt based assay [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl) -2- (4-ulfophenyl) -2H-
tetrazolium, inner salt (MTS)] was employed. MTS 
is the name given to a colorimetric technique for 
assessing cell viability. Viable cells take up the MTS 
into their mitochondria in the presence of phenazine 
methosulfate (PMS) and metabolize it into blue 
formazan crystals, which can be spectrophotometrically 
quantified. MTS was performed to interpret the cell 
viability where 5x103 cells were inoculated in 100 
μL of media, into each well of a 96-well plate, and 
left to incubate overnight to achieve sufficient cell 
attachment to the plate surface. Magnetite-chitosan 
nanobeads were dissolved in cell media for various 
nanoparticle solution concentrations (0.2%, 0.1%, 
0.05%, 0.025% and 0.0125% (w/w)) and filtered 
through 0.2 μm filter, before being introduced to the 
plates. The media on the cells were then aspirated. 
100 μL of suspension containing magnetite-chitosan 
nanobeads were added and incubated for additional 
24 h, 48 h and 72 h in different well-plates. At each 
time interval, the supernatant was carefully removed 
and 110 μL of MTS solutions were added to the plates 
for an additional two-hour incubation. The MTS 
assay was performed in 4 replicates. Additionally, 
background correction was performed due to the dark 
color of magnetite nanoparticles in the medium. For 
background correction, four additional wells were 
employed as controls, which contained the same 
amounts of cells and the particles underwent the same 
treatment steps, but did not received the MTS solution. 
The absorption values obtained from these wells were 
subtracted from those of the sample wells. 
RESULTS AND DISCUSSION
Size and morphology of chitosan-
magnetite nanobeads
The morphology and the size of chitosan nanobeads 
containing functionalized magnetite nanoparticles 
were investigated by Scanning Electron Microscope 
(SEM). Figure 2 shows SEM images of chitosan 
nanobeads prepared by TPP and Na2SO4.10H2O salts, 
latter also in the absence and presence of magnetic 
nanoparticles which were incorporated into the 
nanobeads. SEM results clearly indicate that chitosan 
nanobeads could not be formed in the presence of 
TPP salt while the use of Na2SO4.10H2O lead to the 
formation of roughly 300 nm nanobeads which have 
irregular morphologies and wide size distribution. It 
appears that the particles adhere to each other upon 
drying as no individual particles can be identified with 
SEM. However, the DLS results as will be discussed 
shortly prove that in solution nanobead formation 
has taken place. SEM images also revealed that the 
incorporation of magnetite nanoparticles into the 
nanobeads remarkably decreased the average size of 
the nanobeads (20 nm, Figure 2c). As a consequence, 
utilization of Na2SO4 salt as the precipitating agent 
lead to the formation of magnetic nanobeads with 
satisfactory sizes and morphologies as stated in the 
literature (Parida, Bindhani, 2015; Saita et al., 2011).
Berna Gürten, Elçin Yenigül, Ali Demir Sezer, Cem Altan1, Seyda Malta
Page 6/16 Braz. J. Pharm. Sci. 2020;56: e18579
FIGURE 2 - SEM images of chitosan nanobeads (a) Chitosan nanobeads could not be formed in the presence of TPP salt (b) 






O salt which have irregular morphologies 






O salt, and magnetite nanoparticles 
have comparably smaller size (20 nm).
Size distribution of chitosan- magnetite nanobeads
Size distributions of magnetite-chitosan nanobeads 
with varying chitosan concentrations were investigated 
by DLS. According to the results given in Figure 3, the 
majority of the magnetite-chitosan nanobeads with the final 
concentration of 0.11 wt% have an average hydrodynamic 
diameter of 31±2 nm. Additionally, a minor aggregation 
is suggested by the intensity average plot, as another peak 
around 45 nm is obtained. These values are consistent with 
SEM images, where reduction of size is observed upon 
addition of magnetite to chitosan nanobeads.
On the other hand, when the chitosan amount 
in the nanobeads is increased by a factor of three, a 
relatively narrower size distribution without aggregation 
is obtained where the average hydrodynamic diameter 
of nanobeads is 48 ± 2 nm, as shown in Figure 4. This 
result suggests that an increase in the concentration 
of chitosan during the synthesis lead to an increase 
in the hydrodynamic diameter of magnetite-chitosan 
nanobeads (Omar Zaki, Ibrahim, Katas, 2015; Abdayeh 
et al., 2017).
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= 1.1 wt% ; [chitosan]
final
 =0.11 wt% ; salt + [b-CD coated magnetite]
final
 =2.1 mg/mL). The average 
hydrodynamic diameter of magnetite-chitosan nanobeads are 31±2 nm and minor aggregation is suggested around 45 nm.









= 1.1 wt% ; [chitosan]
final
 =0.33 wt% ; [b-CD coated magnetite]
final
 =2.1 mg/mL). An increase in the chitosan 
amount leads to the formation of relatively larger nanobeads having narrower size distribution without further aggregation. 
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Magnetic properties of the magnetite-
chitosan nanobeads
The suitable application of magnetic nanoparticles 
in magnetic drug targeting systems mostly relies on the 
magnetic properties of the corresponding nanoparticles. 
For these types of drug delivery systems, it is essential 
to implement particles that have optimum saturation 
magnetization and preferably superparamagnetic 
properties as the remaining magnetism in the absence of 
an external magnetic field may lead to aggregation due 
to magnetic interactions resulting in clogging within 
blood channels. Magnetic properties of b-CD-mag-
chitosan nanobeads were measured by VSM and results 
clearly indicate that the obtained nanobeads containing 
magnetite nanoparticles have superparamagnetic 
properties with no coercivity and remaining 
magnetization. As shown in Figure 5, the saturation 
magnetizations of the magnetite-chitosan nanobeads are 
considerably lower, 30.1 emu/g and 21.4 emu/g for 0.2 
wt% and 1 wt% chitosan, respectively than that of bulk 
magnetite (90 emu/g) (Goya, Berquó, Fonseca, 2003; 
Demortiere et al., 2011) which is due to the presence of 
chitosan non-magnetic layer around the magnetic core 
(Yuan et al., 2012). 
FIGURE 5 - VSM data for chitosan-magnetite nanobeads where the magnetite concentration is 3.9 mg/mL Magnetite 
nanoparticles that are incorporated into the nanobeads exhibit superparamagnetic properties and possess lower saturation 
magnetizations as expected due to non-magnetic layer around the particles.
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Surface coating of magnetic nanoparticles
The obtained magnetic nanoparticles, after 
their synthesis in the presence of cyclodextrins, were 
colloidally stable, which suggests either the covalent 
attachment of cyclodextrins onto the surface of 
these particles or via electrostatic interactions at the 
surface. The nature of these interactions are beyond 
the scope of this paper, however the longevity of these 
colloidal particles is desired. The amounts of CDs on 
the surface of magnetite nanoparticles are revealed by 
using the thermogravimetric analysis (TGA). For these 
measurements, nanoparticles were washed with water 
and then dried in a vacuum oven at 60 ºC overnight. 
Bare nanoparticles show an initial weight loss of 
approximately 1.74 wt. % till 150 ºC which is attributed 
to the evaporation of adsorbed water while further 
weight loss of 2.63 wt. % until 600 ºC may be attributed 
to the impurities within the sample, as shown in Figure 
6,. For the functionalized magnetite nanoparticles, the 
weight losses observed in the 150-600 ºC interval are 
due to the presence of organic layer (i.e. CD coating) on 
the surface of the particles 
In addition, the onset temperature being unique to 
the compound can be used to determine the presence 
of coating on the particle surface. According to the 
weight loss profiles given in Figure 5, bare b-CD has 
an onset temperature of 353 ºC, which is consistent 
with literature, while b-CD functionalized magnetite 
nanoparticles have an onset temperature of 202 ºC. 
Additionally, weight loss profiles of H-γ-CD and H-b-
CD functionalized magnetite nanoparticles have an onset 
temperatures of 243 ºC and 245 ºC respectively. These 
results clearly show that there exist temperature shifts on 
the onset temperatures for CD functionalized magnetite 
nanoparticles, indicating successful attachment of CDs 
onto the surface of magnetite nanoparticles. It should be 
FIGURE 6 - Thermogravimetric analysis for magnetite with and without CD’s. The initial weight loss observed for all samples 
up to ~100 – 120 ºC are attributed to the removal of adsorbed water and further losses are due to the organic layer around 
the particles. The highest amount of CD coating is observed for b-CD coated magnetite nanoparticles (~18%) and the wt.% 
difference between the two plateaus at 150 ˚C and 600 ˚C are tabulated in Table I as % coating of magnetite nanoparticles with 
different type of CD’s.
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noted that the highest amount of CD coating is achieved 
with b-CD (about 18 wt.% loss as compared to about 
4 and 3 wt.% for H-b-CD and H-γ-CD, respectively) 
where the highest shift in onset temperature is also 
observed. As more CD molecules reside on the magnetite 
surface, the change in onset temperature becomes more 
pronounced. Finally, these results show that magnetite 
particles were successfully functionalized with all types 
of CD’s but at varying coating densities.
TABLE I - Percentage coating of magnetite nanoparticles with 
different CD’s
Type of cyclodextrins
wt. loss%  




Encapsulation of TMZ in chitosan-
magnetite nanobeads
Feasible application of magnetite-chitosan 
nanobeads as a drug delivery system essentially relies 
on the drug encapsulation efficiency of the nanobeads. 
Temozolomide has been encapsulated in liposomes. 
Although some progress in some cancer treatments has 
been made over the years, there is still no definitive 
treatment available for Glioblastoma multiforme 
(GBM). It has been demonstrated that the currently 
limited efficacy of convection-enhanced delivery (CED) 
could be enhanced by a liposomal formulation, thus 
achieving enhanced TMZ localization to the tumor 
site with minimal toxicity. On the other hand, a novel 
approach has been described for treating GBM by CED 
of (PEGylated) liposomes containing TMZ, the known 
chemotherapeutic agent (Vanza et al., 2018; Lin et al., 
2018.; Nordling-David et al., 2017). However, to our 
knowledge no magnetic targeting of temozolomide 
is ever presented in the literature. In order to study 
the encapsulation extent of chemotherapeutic drug 
temozolomide in the magnetite-chitosan nanobeads, the 
concentration of CD modified magnetite nanoparticles 
was kept at 0.5 wt.%, and the concentration of precipitating 
salt and chitosan were varied. The encapsulated 
amount of TMZ in magnetite-chitosan nanobeads was 
measured by HPLC and the corresponding results are 
shown in Table II. At a fixed concentration of chitosan, 
an increase in the concentration of salt either do not 
alter or adversely affect the encapsulation efficiency 
of TMZ in magnetite-chitosan nanobeads, as shown in 
Table II,. Except for H-γ-CD functionalized magnetite 
nanoparticles, keeping the chitosan concentration 0.22 
wt.% and increasing the salt concentration from 1.1 to 
2.2 wt.% lead to a decrease in the encapsulated TMZ 
amount, whereas for higher chitosan concentrations, 
the encapsulated amount of drug remains essentially 
unaffected. For H-γ-CD functionalized magnetite 
nanoparticles at 1.1 wt.% final salt concentration, 
increasing chitosan amount results in an increase in 
the encapsulated TMZ amount. These results indicate 
that the final concentrations of chitosan and salt have a 
delicate balance in optimization of the amount of TMZ 
encapsulated in magnetite-chitosan nanobeads.
For targeting studies, TMZ loaded b-CD-
magnetite-chitosan nanobeads were circulated in a 
closed system and for comparison collected at different 
test sections which have different inner diameters 
of 1.49 mm (Section I) and 2.19 mm (Section II), by 
applying 0.3 T and 0.5 T magnetic fields, respectively. 
Once magnetite-chitosan nanobeads are collected in the 
specified test sections, the amounts of chitosan, TMZ 
as well as magnetite nanoparticles were calculated and 
tabulated in Table III. 
The results indicated that, when nanobead bearing 
nanofluid flowed within the closed system and an 
external magnetic field strength of 0.3 T was applied, 
an insignificant amount of TMZ (~0.1mg) was collected 
as compared to the initial amount (0.01 g) in the smaller 
diameter test section regardless of the concentration 
of chitosan and salt as shown in III. The high ratio of 
the collected TMZ to chitosan is an indication of the 
formation of a successful drug carrier and using small 
diameter and low magnetic field did not result in a 
satisfactory ratio.
To improve the amount of collected TMZ with respect 
to the magnetic carrier, targeting experiments were also 
performed by using a larger diameter test section and 
applying an enhanced external magnetic field strength of 
0.5 T. The results shown in Table IV clearly indicate that 
an increase in the test section diameter as along with an 
increase in the external magnetic field strength increased 
the amount of nanobead collected, thus TMZ targeted. 
Targeting of temozolomide using magnetic nanobeads: an in vitro study
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with b-CD coated 
magnetite
(% encapsulation)
with H-b-CD coated 
magnetite
(% encapsulation)
with H-γ-CD coated 
magnetite
(% encapsulation)
0.22 1.1 35.0 ± 2.8 37.0 ± 3.9 29.0 ± 2.7
0.22 2.2 16.5 ± 1.1 20.0 ± 2.4 26.0 ± 2.1
0.33 1.1 35.5 ± 7.8 39.0 ± 4.1 36.0 ± 5.2
0.33 2.2 35.0 ± 3.4 32.0 ± 4.8 19.0 ± 3.2
0.43 1.1 35.5 ± 3.5 38.0 ± 3.6 45.0 ± 5.6
0.43 2.2 37.5 ± 3.5 41.0 ± 4.2 45.0 ± 4.8
Targeting of TMZ loaded magnetite-chitosan nanobeads
























0.22 2.2 0.35± 0.03 0.28± 0.02 0.09± 0.008 0.26± 0.007
0.43 2.2 0.23± 0.02 0.09± 0.01 0.08± 0.01 0.35± 0.009
0.09 1.1 0.25± 0.02 0.49± 0.05 0.12± 0.07 0.48± 0.01
0.22 1.1 0.23± 0.03 0.18± 0.009 0.11± 0.009 0.48± 0.008
0.33 1.1 0.48± 0.04 0.25± 0.02 0.10± 0.01 0.21± 0.008
For instance, magnetite-chitosan nanobeads which 
have final concentrations of 0.43 wt.% and 2.2 wt.% 
chitosan and salt, respectively led to the collection 
of approximately 0.32 mg of TMZ in the test section, 
where the ratio of the collected TMZ to chitosan was 
0.47. However, magnetite-chitosan nanobeads which 
contain 0.09 wt.% final chitosan and 2.2 wt.% final salt 
concentrations, approximately 0.27 mg was collected 
in the desired area and the ratio of the collected TMZ 
to chitosan was 1.05. Although more TMZ might be 
collected with higher amounts of chitosan, large ratio of 
collected TMZ to chitosan value is desired for efficiency. 
Therefore, nanobeads with low concentration of chitosan 
may be more suitable as nanocarriers. It is known in the 
literature that any matrix which is not magnetic around 
a magnetic material reduces the magnetizability of the 
carrier (Yuan et al., 2012). If the non-magnetic material 
is what carries the drug (as it is in this case), although 
it is tempting to increase the encapsulated amount of 
drug by increasing the nonmagnetic matrix, it may 
result in the reduction of saturation magnetization, thus 
the loss of ability of magnetic capture of these particles 
(Ghazanfari et al., 2016) Based on the results, an optimum 
concentration of 0.09 wt.% final chitosan concentration 
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was suggested with two different final concentrations 
of salt (1.1 wt.% and 2.2 wt%). It should be noted that 
as chitosan concentration in the nanobeads decreases, 
saturation magnetization of the nanobeads increases 
(shown with VSM results). This leads to an increase in 
the captured magnetite (i.e. nanobeads) amount, which 
is responsible for the high amount of TMZ captured with 
respect to the amount of novel drug carrier.
Stability studies
The colloidal stability of functionalized magnetite 
nanoparticles was investigated by time resolved settling 
experiments and compared with bare magnetite 
nanoparticles. Table V shows that, bare nanoparticles 
precipitate within 15 minutes due to lack of any surface 
modifications preventing agglomeration. On the other 
hand, all the functionalized magnetite nanoparticles 
showed enhanced and suitable colloidal stability where 
the longest stability was obtained with 2-hydroxypropyl 
b-CD (> 5 hours). These settling times are remarkably 
enhanced in acidic environment where studies with TMZ 
were carried out. Although some other stabilizers could 
be used as coating material, CDs are well-established 
drug carriers which are known to be not only non-toxic 
but also biocompatible (Bai et al., 2018; Garnero et al., 
2018; Kim et al., 2018). 
TABLE V - Settle time for different CDs coated magnetic 
nanoparticles
Sample Time to Precipitation
Bare magnetite 15 minutes
Magnetite with b-CD 55 minutes
Magnetite with > 5 hours
Magnetite with 40 minutes
Cytotoxicity studies
In vitro cytotoxicity studies were performed for both 
bare and b-CD coated magnetite nanoparticles (b-CD-
mag) as well as b-CD-mag-chitosan nanobeads. As 
functionalized magnetite nanoparticles are intended to 
be used for biomedical applications, it is important that 
they do not possess toxicity for cells. Figure 6 shows the 
viability of cells after three days and it is clearly observed 
that bare magnetite nanoparticles do not exhibit toxicity at 
least until 330 μg/mL. On the other hand, cell viability was 
further enhanced upon functionalization of these particles 
with various types of CDs (almost up to 800 μg/mL). In 
the literature, superparamagnetic magnetite nanoparticles 






















0.09 1.1 0.32 ± 0.01 0.63 ± 0.01 0.27 ± 0.03 0.82 ± 0.09
0.09 2.2 0.26 ± 0.02 0.51 ± 0.04 0.27 ± 0.01 1.05 ± 0.05
0.22 1.1 0.72 ± 0.03 0.56 ± 0.02 0.33 ± 0.02 0.44 ± 0.01
0.22 2.2 0.33 ± 0.02 0.26 ± 0.02 0.25 ± 0.02 0.75 ± 0.08
0.33 1.1 0.84 ± 0.06 0.44 ± 0.03 0.31 ± 0.03 0.37 ± 0.07
0.33 2.2 0.73 ± 0.09 0.38 ± 0.05 0.29 ± 0.01 0.53 ± 0.20
0.43 1.1 0.52 ± 0.14 0.21 ± 0.05 0.27 ± 0.03 0.53 ± 0.15
0.43 2.2 0.68 ± 0.17 0.27 ± 0.07 0.32 ± 0.05 0.47 ± 0.05
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was shown to have a dose dependent toxicity (Darroudi 
et al., 2014) while ferromagnetic magnetite nanoparticles 
were shown to be non-toxic up to 1000 μg/mL, where 
biocompatibility was enhanced upon coating with PAA 
polymer (Altan et al., 2016). Chitosan has been used 
in biomedical applications for decades. Chitosan is an 
effective material for biomedical applications because of its 
biocompatibility, biodegradability and non-toxicity, apart 
from their antimicrobial activity and low immunogenicity. 
Chitosan-based biomaterials have become a popular 
target in the development of tissue engineering and 
significant progress has recently been made. It provides 
certain mechanical and structural properties for proper 
functioning for the repaired tissues (Khan et al., 2018; 
Fiqrianti et al., 2018; Sun, Lee, Zhang, 2018).
Encapsulation of b--CD coated magnetite 
nanoparticles in chitosan nanobeads further increased 
the biocompatibility of the particles (non-toxic up to 
2000 μg/mL), leading to a promising magnetic carrier 
for biomedical applications, as seen in Figure 7,. 
CONCLUSION
The chemotherapeutic drug, TMZ which is often 
employed against brain cancers is encapsulated in a 
magnetic carrier, where chitosan is the drug embedded 
polymer and magnetite nanoparticles are responsible for 
the magnetic targeting. 
Magnetite nanoparticles, synthesized by the 
coprecipitation method are surface modified with CDs 
which are hydrophilic molecules with hydrophobic 
cavities, to accommodate TMZ. These magnetic 
nanoparticles are then embedded in chitosan nanobeads 
prepared by salt addition. Magnetic properties of 
the developed vehicle are shown to be sufficient to 
accumulate the nanocarrier (i.e. magnetic nanobeads) in 
FIGURE 7 - Cell Viability versus magnetite concentration for CD-coated magnetite nanoparticles and chitosan embedded 
magnetite nanobeads. The connecting lines are placed as a guide to the eye. Magnetite nanoparticles do not possess toxicity of 
up to 330 µg/mL, while viability further increased after functionalization of particles by different types of CDs. Encapsulation 
of b-CD functionalized magnetite nanoparticles in chitosan nanobeads further increased the biocompatibility of the particles.
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a target area by the application of the 0.5 T magnetic 
field, which makes these particles suitable for targeted 
drug delivery applications.
Experimental conditions are optimized to 
maximize the amount of targeted TMZ, minimizing 
the amount of chitosan used in the nanobead. An 
optimum concentration of 0.09 wt.% final chitosan 
concentration can be suggested at a final salt 
concentration of 2.2 wt%. As the chitosan amount 
increases with respect to magnetite, the magnetic 
properties of the carrier decrease which diminishes 
the ability to target these nanobeads in the desired 
area. Therefore, a delicate balance between the 
amount of TMZ, magnetite and chitosan exists. To 
our knowledge this is the first study which shows that 
TMZ can be targeted using a suitable nanocarrier.
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